Form 4: Eliem Therapeutics Officer Emily Pimblett Executes Stock Transactions

Emily Pimblett, Chief Accounting Officer of Eliem Therapeutics, recently executed transactions involving the company's common stock, including the conversion of restricted stock units and sales under a pre-arranged trading plan.

Summary

• Emily Pimblett, Chief Accounting Officer of Eliem Therapeutics, converted 5,000 restricted stock units (RSUs) into common stock on September 18, 2024.
• She then sold 1,182 shares of common stock at $8.18 per share and 9 shares at $8.06 per share on September 20, 2024.
• These sales were conducted under a 10b5-1 trading plan adopted on April 27, 2024, to cover tax withholding obligations related to the vesting of her RSUs.
• Following these transactions, Pimblett directly owns 7,564 shares of Eliem Therapeutics common stock and 30,000 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't convey strong positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold.

Key Dates